|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Labetalol#Patient Counseling Information]] |
| {{Labetalol}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Patient Counseling Information==
| |
| | |
| As with all drugs with beta-blocking activity, certain advice to patients being treated with labetalol HCl is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects. While no incident of the abrupt withdrawal phenomenon (exacerbation of angina pectoris) has been reported with labetalol HCl, dosing with labetalol hydrochloride tablets should not be interrupted or discontinued without a physician's advice. Patients being treated with labetalol hydrochloride tabletsshould consult a physician at any signs or symptoms of impending cardiac failure or hepatic dysfunction (seeWARNINGS). Also, transient scalp tingling may occur, usually when treatment with labetalol hydrochloride tabletsis initiated (see ADVERSE REACTIONS).
| |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LABETALOL HYDROCHLORIDE INJECTION, SOLUTION [HOSPIRA, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=abfc6b75-1ed5-41f1-0484-4597488237bc | publisher = | date = | accessdate = 5 February 2014 }}</ref>
| |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Beta blockers]]
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |
| {{WikiDoc Help Menu}}
| |
| | |
| {{WikiDoc Sources}}
| |